Recall Register

Food, drugs, devices › Aurobindo Pharma USA Inc

Drug recall: Gabapentin Capsules, USP 300 mg, 100-count bottles, Rx only, Manufactured for: Northstar Rx LLC, Memphis, TN 38141; Manu

FDA enforcement event 69807 · Class II · initiated 17 Oct 2014 · status Terminated · terminated 23 May 2016

DrugVoluntary: Firm initiated1 product recordDayton, NJ

FDA enforcement event 69807 is a drug recall by Aurobindo Pharma USA Inc of Dayton, NJ, initiated 17 Oct 2014 and classified Class II, with 1 product record.

FDA defines Class II as a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. 58% of the 313 drug enforcement events initiated in 2014 carry the same class.

Status: Terminated, terminated 23 May 2016. Initiation: voluntary: firm initiated. Aurobindo Pharma USA Inc has 33 enforcement events on this register, with a median of 1 product record per event.

Recall classification reflects the relative degree of health hazard. Text in quotation marks is FDA's. openFDA export dated 28 Sep 2026.

Recalling firm

Aurobindo Pharma USA Inc, Dayton, NJ.

Reason for recall

"Failed Tablet/Capsule Specifications: Complaints of empty capsules received."

Distribution

"Nationwide"

Product records

Recall numberProductQuantityClassStatusReport date
D-0330-2015Gabapentin Capsules, USP 300 mg, 100-count bottles, Rx only, Manufactured for: Northstar Rx LLC, Memphis, TN 38141; Manufactured by: Aurobindo Pharma Limited, Unit-VII (SEZ), Mahaboob Nagar (Dt), AP-509302, INDIA, NDC 16714-662-01, UPC 3 16714-662-01 5.24,816 bottlesClass IITerminated14 Jan 2015

Context

58%of 2014 drug events are Class II313 events that year
1product record in this eventfirm median: 1
33events on this register for the firm

Other enforcement events for Aurobindo Pharma USA Inc

InitiatedProduct (first record)TypeClassRecords
23 Jul 2026Dicyclomine Hydrochloride Capsules, USP, 10mg, 1,000 bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc., 279 PDrugClass II1
22 May 2025Acetaminophen Tablets, 325 mg, 100-count bottles, Distributed by: Amazon.com Services LLC, 410 Terry Avenue N., Seattle,DrugClass II1
6 Dec 2024Nebivolol Tablets, 2.5. mg, 30-count bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc., 279 Princeton-HightstDrugClass II1
7 Nov 2024Cinacalcet Tablets, 30 mg, packaged in: a) 30-count HDPE bottle (NDC 65862-831-30); b) 500-count HDPE bottle (NDC 65862-DrugClass II3
11 Jul 2024Healthy Living Acetaminophen, Aspirin (NSAID) and Caffeine, tablets USP, 250 mg/250 mg/65 mg, 100-count bottles, DistribDrugClass I1
24 Apr 2024Clorazepate Dipotassium Tablets, USP, 3.75 mg, a) 100 tablets per bottle, NDC 13107-282-01 b) 500 tablets per bottle, NDDrugClass II2
2 Aug 2023Rasagiline Tablets 0.5mg, 30-count bottle, Rx only, Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A., NDC 0378-127DrugClass II1
21 Jul 2023Rufinamide Tablets, USP 200 mg, packaged in 120-count bottle, Rx only, Distributed by: Aurobindo Pharma USA, Inc., 279 PDrugClass II2
22 May 2023Pain Reliever, Acetaminophen USP Caplets, 500 mg, 225-count bottles packaged in a cardboard carton, Distributed by: WalgDrugClass II1
5 Oct 2022Quinapril and Hydrochlorothiazide Tablets, USP 20mg/12.5mg, 90 Tablets bottles Distributed by: Aurobindo Pharma USA, IncDrugClass II1

All 33 events for Aurobindo Pharma USA Inc

Questions and answers

Why was this drug recalled?

FDA's record gives the reason for recall as: "Failed Tablet/Capsule Specifications: Complaints of empty capsules received."

What does Class II mean?

FDA classifies recalls by relative degree of health hazard. Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Where was the product distributed?

FDA's distribution pattern field reads: "Nationwide"

Is the recall still ongoing?

FDA lists the status as Terminated; the termination date is 23 May 2016. "Terminated" means FDA has determined that all reasonable efforts to remove or correct the product have been made.

Where does this data come from?

openFDA enforcement reports (food, drug and device), CC0, export dated 28 Sep 2026. Text in quotation marks is FDA's. The FDA enforcement report linked above is authoritative.

Provenance

Source: openFDA drug enforcement reports (CC0), export dated 28 Sep 2026; records grouped by FDA event number. The class shown for the event is the most severe class among its records. Errors in processing are corrected at the next build; see corrections.